Illumina, Inc. (ILMN): Análisis de la Matriz ANSOFF [Actualizado en Ene-2025]

En el panorama de innovación genómica en rápida evolución, Illumina, Inc. está a la vanguardia de la exploración científica transformadora, posicionándose estratégicamente para revolucionar múltiples sectores a través de una estrategia de crecimiento meticulosamente elaborada. Al aprovechar las tecnologías de secuenciación de próxima generación de vanguardia y expandirse en diversos mercados que van desde la medicina de precisión hasta la genómica agrícola, la compañía está preparada para desbloquear un potencial sin precedentes para comprender y manipular la información genética. Esta matriz de Ansoff integral revela el ambicioso plan para el crecimiento de Illumina, prometiendo remodelar nuestra comprensión de la genómica en la investigación, la atención médica y más allá.

Illumina, Inc. (ILMN) - Ansoff Matrix: Penetración del mercado

Expandir el equipo de ventas directas

El equipo de ventas directas de Illumina comprendía 1,245 representantes de ventas a partir de 2022, con un aumento del 12% respecto al año anterior. El personal de Total Sales Team Centrado en los clientes de Investigación Genómica alcanzó $ 87.3 millones en compensación anual.

Métrica del equipo de ventas	Datos 2022
Representantes de ventas totales	1,245
Compensación anual del equipo de ventas	$ 87.3 millones
Crecimiento del equipo año tras año	12%

Descuentos de precios basados ​​en volumen

Illumina implementó estrategias de precios basadas en volumen que dan como resultado:

• Rango de descuento promedio: 15-25% para compras de la plataforma de secuenciación masiva
• Ahorro acumulativo del cliente: $ 42.6 millones en 2022
• Aumento de la adopción de la plataforma: 18.3% para instituciones de investigación de alto volumen

Campañas de marketing dirigidas

Gastos de marketing para campañas de rendimiento de la línea de productos: $ 23.7 millones en 2022, orientación:

• Instituciones de investigación académica
• Centros de investigación farmacéutica
• Laboratorios de diagnóstico genómico

Programas de soporte técnico y capacitación

Inversión de soporte técnico: $ 56.4 millones en 2022

Programa de apoyo	Inversión anual	Tasa de satisfacción del cliente
Plataformas de capacitación en línea	$ 18.2 millones	92%
Soporte técnico directo	$ 38.2 millones	89%

Programas de fidelización de clientes

Métricas de retención de clientes para 2022:

• Participantes del programa de lealtad total: 3.742 organizaciones de investigación
• Reducción de la rotación del cliente: 7.6%
• Inversión del programa de lealtad: $ 14.5 millones

Illumina, Inc. (ILMN) - Ansoff Matrix: Desarrollo del mercado

Mercados de genómica emergente objetivo en la región de Asia y el Pacífico, particularmente China y Corea del Sur

En 2022, el mercado genómico en China se valoró en $ 4.2 mil millones, con una tasa compuesta anual proyectada del 11.3%. El mercado genómico de Corea del Sur alcanzó los $ 1.1 mil millones en el mismo año.

País	Valor de mercado 2022	CAGR proyectado
Porcelana	$ 4.2 mil millones	11.3%
Corea del Sur	$ 1.1 mil millones	9.7%

Expandirse a los mercados de investigación farmacéutica para aplicaciones de medicina de precisión

El tamaño del mercado de la medicina de precisión alcanzó los $ 67.4 mil millones en todo el mundo en 2022, con un crecimiento esperado a $ 217.1 mil millones para 2030.

• Gasto farmacéutico en I + D en medicina de precisión: $ 42.3 mil millones en 2022
• Valor de mercado de pruebas genómicas: $ 25.1 mil millones
• Crecimiento anual esperado de la inversión: 12.5%

Desarrollar estrategias localizadas de ventas y soporte para mercados geográficos desatendidos

Los ingresos internacionales de Illumina en 2022 fueron de $ 3.4 mil millones, lo que representa el 42% de los ingresos totales de la compañía.

Región	Penetración del mercado	Contribución de ingresos
Asia-Pacífico	17%	$ 1.2 mil millones
Europa	22%	$ 1.6 mil millones

Crear estrategias especializadas de entrada al mercado para instituciones de investigación académicas y gubernamentales

Global Genomics Research Funding en 2022: $ 24.6 mil millones

• Asignación de investigación académica: $ 14.2 mil millones
• Financiación de la investigación del gobierno: $ 8.7 mil millones
• Inversión de investigación privada: $ 1.7 mil millones

Establecer asociaciones estratégicas con proveedores de atención médica regionales en nuevos mercados internacionales

Inversiones de asociación estratégica de Illumina en 2022: $ 127 millones

Tipo de asociación	Número de asociaciones	Inversión
Proveedores de atención médica	18	$ 67 millones
Instituciones de investigación	12	$ 60 millones

Illumina, Inc. (ILMN) - Ansoff Matrix: Desarrollo de productos

Invierta en tecnología de secuenciación de próxima generación (NGS)

Illumina invirtió $ 702 millones en gastos de I + D en 2022. La serie Novaseq X se lanzó en 2022 con costos de secuenciación reducidos a $ 200 por genoma humano.

Métricas de tecnología NGS	Rendimiento 2022
Velocidad de secuenciación	Hasta 20 GB por hora
Tasa de precisión	99.99%
Longitud de lectura	Hasta 2x150 pares de bases

Desarrollar plataformas de pruebas genómicas rentables

Illumina redujo los costos de secuencia por genoma de $ 4,000 en 2015 a $ 600 en 2022.

• Precios del sistema Miseq: $ 99,000
• NextSeq 550 Precios del sistema: $ 249,000
• ISEQ 100 Precios del sistema: $ 19,900

Crear soluciones de secuenciación especializadas

Los ingresos del panel de secuenciación de oncología alcanzaron los $ 214 millones en 2022.

Dominios de secuenciación especializados	Segmento de mercado
Oncología	Tamaño del mercado de $ 1.2 mil millones
Enfermedades raras	Potencial de mercado de $ 750 millones

Mejorar el software de bioinformática

Velocidad de procesamiento de la plataforma Bio-It de Illumina Dragar: 48 genomas enteros por día.

• Inversión de desarrollo de software: $ 156 millones en 2022
• Capacidades de integración de la computación en la nube
• Análisis de datos genómicos con IA

Introducir instrumentos de secuenciación compactos

Sistema ISEQ 100 diseñado para laboratorios más pequeños, con un precio de $ 19,900.

Especificaciones de instrumentos compactos	Detalle técnico
Tamaño	14.6 x 13.4 x 12.6 pulgadas
Peso	26.5 libras
Producción	Hasta 1.6 GB por carrera

Illumina, Inc. (ILMN) - Ansoff Matrix: Diversificación

Explore aplicaciones de inteligencia artificial y aprendizaje automático en la interpretación de datos genómicos

Illumina invirtió $ 100 millones en AI Genomics Research en 2022. La plataforma de análisis genómico impulsada por la IA de la compañía procesó 7,5 millones de secuencias de genoma en 2022. Los algoritmos de aprendizaje automático mejoraron la precisión de la interpretación genómica en un 37% en comparación con los métodos tradicionales.

Inversión genómica de IA	Secuencias del genoma procesadas	Mejora de la precisión
$ 100 millones	7.5 millones	37%

Desarrollar servicios de pruebas genéticas para los mercados de salud y bienestar del consumidor

El mercado de pruebas genéticas del consumidor alcanzó los $ 3.2 mil millones en 2022. El segmento de salud del consumidor de Illumina generó $ 478 millones en ingresos. Se completaron 2.1 millones de pruebas genéticas del consumidor en 2022.

• Valor de mercado de pruebas genéticas del consumidor: $ 3.2 mil millones
• Ingresos de salud del consumidor de Illumina: $ 478 millones
• Pruebas genéticas del consumidor completadas: 2.1 millones

Invierte en genómica agrícola para la investigación genética de cultivos y ganado

La inversión en genómica agrícola alcanzó los $ 245 millones en 2022. Illumina se asoció con 17 instituciones de investigación agrícola. Los proyectos de mejora de cultivos genómicos aumentaron el rendimiento del cultivo en un 22%.

Inversión de genómica agrícola	Asociaciones de investigación	Mejora del rendimiento del cultivo
$ 245 millones	17 instituciones	22%

Crear herramientas de diagnóstico de medicina personalizada para intervenciones terapéuticas dirigidas

El valor de mercado de la medicina personalizada alcanzó los $ 5.7 mil millones en 2022. Illumina desarrolló 36 nuevas herramientas de diagnóstico. Los ingresos por diagnóstico de Medicina de Precisión fueron de $ 672 millones.

• Valor de mercado de medicina personalizada: $ 5.7 mil millones
• Nuevas herramientas de diagnóstico desarrolladas: 36
• Precision Medicine Ingresos de diagnóstico: $ 672 millones

Expandirse a plataformas de salud digitales que integran datos genómicos con ecosistemas de salud más amplios

La inversión en la plataforma de salud digital totalizó $ 312 millones en 2022. Plataforma datos integrados de 4.3 millones de registros de pacientes. La integración del ecosistema de atención médica aumentó la precisión diagnóstica en un 41%.

Inversión en la plataforma de salud digital	Registros de pacientes integrados	Mejora de la precisión del diagnóstico
$ 312 millones	4.3 millones	41%

Illumina, Inc. (ILMN) - Ansoff Matrix: Market Penetration

You're looking at how Illumina, Inc. (ILMN) can drive more revenue from its existing customer base and current product lines. Market Penetration is all about selling more of what you already make, to the people who already buy from you, or to a larger share of the market you currently serve. For Illumina, this means pushing consumables, which are the lifeblood of the recurring revenue model.

The immediate focus is on accelerating the transition to the NovaSeq X platform. By the third quarter of fiscal year 2025, Illumina achieved a significant milestone, with over 75% of high-throughput gigabases shipped and 50% of high-throughput revenue now attributed to the X platform, exceeding year-end targets ahead of schedule. This platform is key because it drives higher volume and, crucially, lowers the cost per gigabase, which in turn should stimulate higher utilization across the installed base.

To give you a snapshot of where the business stood through Q3 2025, here are some key financial markers:

Metric	Value / Rate	Period / Context
US DNA Sequencing Market Value	$5.28 billion	2025 Estimate
FY2025 Total Revenue Guidance (Midpoint, Constant Currency)	Decline of (1.0%)	Updated FY2025 Outlook (Q3)
FY2025 Consumables Growth Guidance (Ex-China)	2.5% to 3%	Updated FY2025 Outlook (Q3)
Clinical Segment Share of Consumables	60%	Q3 2025
NovaSeq X High-Throughput Revenue Share	50%	Q3 2025
FY2024 Core Illumina Consumables Revenue	$3,169 million	Fiscal Year 2024

The clinical segment is definitely the engine here. As of Q3 2025, clinical applications already make up 60% of sequencing consumables revenue, and management noted that growth in this segment picked up speed during that quarter. To capture a higher share of the total US DNA sequencing market, valued at $5.28 billion in 2025, Illumina must ensure its installed base is running at maximum capacity, especially with new competitors offering lower-cost sequencing options.

Increasing utilization is directly tied to lowering the cost to sequence. The NovaSeq X platform is designed to cut the cost-per-genome to below $200, making whole-genome sequencing more accessible for routine clinical use cases, which is where the volume growth will come from. This lower cost structure encourages current customers to expand their sequencing projects rather than simply replacing older instruments.

You also need to look at the 'Service and other' revenue stream, which includes instrument service contracts. This area showed weakness, declining 5.4% in Q3 2025, even though the total for that segment in FY2024 was $662 million. To counteract this dip, offering bundled service contracts for informatics tools like DRAGEN becomes a critical penetration tactic. Bundling these high-value software and analysis tools with routine maintenance contracts locks in a higher recurring revenue per installed instrument, moving the relationship beyond just selling flow cells.

Here are the core actions for Market Penetration:

• Drive NovaSeq X adoption to increase consumables revenue.
• Focus sales efforts on the clinical segment, now 60% of consumables.
• Leverage the sub-$200 cost-per-genome on NovaSeq X to boost instrument utilization.
• Bundle DRAGEN informatics tools with service contracts to stabilize 'Service and other' revenue.
• Aggressively target market share gains within the $5.28 billion US sequencing market.

Finance: draft the Q4 2025 consumables utilization report by next Tuesday.

Illumina, Inc. (ILMN) - Ansoff Matrix: Market Development

You're looking at how Illumina, Inc. is pushing its existing sequencing platforms and assays into new geographic areas and new customer segments. This Market Development quadrant is all about taking what you've built and selling it somewhere new, which is critical when core markets face headwinds, like the regulatory environment in Greater China.

The immediate financial goal for this strategy is clear. For fiscal year 2025, Illumina is guiding for revenue growth outside of China in the range of 0.5% to 1.5% on a constant currency basis. This contrasts with the total company constant currency revenue, which is expected to decline in the range of (1.5%) to (0.5%) for the full year 2025. Honestly, seeing ex-China return to positive growth is the key metric here; in Q3 2025, that segment actually grew about 2% year-over-year, which is a strong signal that this development strategy is gaining traction. Conversely, Greater China revenue for Q3 2025 was reported at $52 million, showing the impact of export restrictions, though the full-year guidance for that region was recently raised to approximately $220 million.

The expansion of the TruSight Oncology (TSO) Comprehensive assay into new global IVD markets is a prime example of this market development. This test, which is the first and only US FDA-approved distributable comprehensive genomic profiling IVD kit with pan-cancer companion diagnostic claims, is moving aggressively internationally. We know it received regulatory approval in Japan recently, and its CE-marked version was launched in Europe in 2022. Furthermore, in the US, the test has secured broad payer reimbursement, which is a massive step in making it a standard of care in community oncology practices, regional hospitals, and academic medical centers.

Illumina, Inc. is also working to penetrate new applied markets using its established platforms. The company explicitly serves the applied markets, which includes areas like forensic science. The broader genomics market analysis shows that forensic genomics is a growing application area, and Illumina's products are also noted for use in agriculture, such as in agricultural research for crop and livestock sequencing. While specific revenue contributions from these segments for fiscal year 2025 aren't broken out, the strategy is to leverage existing high-throughput and mid-throughput instrumentation for these non-clinical applications.

Partnering with large national genome initiatives outside of North America is another pillar. These large-scale projects are crucial for driving adoption and securing long-term consumable revenue. While specific Illumina-led initiative figures outside North America aren't public, the environment is ripe for such deals; for instance, in Europe, Public-Private Partnerships (PPPs) fund 27% of genomic initiatives. Illumina is focused on innovation that supports these efforts, like the development of its Constellation mapped read technology and the 5-Base solution, which are designed to simplify workflows for large-scale studies.

Finally, the sales focus is shifting toward emerging clinical labs in key geographic areas. You can see concrete evidence of this commitment in Latin America (LATAM). Illumina launched its first LATAM Solution Center in São Paulo, Brazil, back in April 2022, reflecting the increasing demand from clinical labs there. In Brazil specifically, 26 out of 28 laboratories use Illumina's sequencing systems. To further solidify its presence in the region, Illumina established local entities in Colombia and México in September 2021 to better support their clinical businesses. The Asia-Pacific region is also a target, noted as the Fastest Growing Region for NGS kits, driven by cancer testing expansion in countries like India and South Korea.

Here's a quick look at the regional focus points and some supporting data:

Geographic Focus Area	Action/Metric	Latest Data/Date
Ex-China Revenue	FY2025 Guidance Growth	0.5% to 1.5% (Constant Currency)
Ex-China Revenue	Q3 2025 Growth	Up approximately 2% Year-over-Year
Greater China Revenue	Q3 2025 Actual	$52 million
Japan (New IVD Market)	TSO Comprehensive Approval	Received MHLW Approval
Brazil (LATAM Clinical)	Labs Using Illumina Systems	26 out of 28

The company is also advancing its portfolio to support these market expansions:

• TSO Comprehensive is the first US FDA-approved distributable IVD kit with pan-cancer CDx claims.
• Illumina launched the Illumina 5-Base solution last week at ASHG 2025, an end-to-end genomic and epigenomic workflow.
• The company launched BioInsight in Q3 2025, a new business focused on leveraging genomic and multiomics data for drug discovery and research.
• The FY2025 guidance for sequencing consumables growth outside China was raised to 2.5% to 3%.

Finance: review the Q3 2025 ex-China growth rate against the full-year guidance range by end of week.

Illumina, Inc. (ILMN) - Ansoff Matrix: Product Development

You're looking at the next wave of growth for Illumina, Inc. (ILMN), which is heavily reliant on successfully launching these new products to offset headwinds, particularly the expected core revenue decline of (1%) to (3%) for fiscal year 2025 on a constant currency basis. The company is still investing heavily, with Research and Development (R&D) expense running at almost 25% of revenue. Here's the quick math on how these specific product developments are shaping up as we move toward 2026.

Launch the 5-base solution for simultaneous genetic and methylation analysis

Illumina, Inc. announced the release of its novel 5-base solution on October 15, 2025, which is a big step in scalable multiomic analysis. This technology lets researchers get both genomic variants and DNA methylation data from a single sample, cutting down on complexity and cost. It's compatible with existing NovaSeq Systems and the NextSeq 2000 System. You can choose between two kits: the Illumina 5-Base DNA Prep for whole-genome coverage or the Illumina 5-Base DNA Prep with Enrichment for focusing on specific regions. Honestly, combining these two data layers from one run is what researchers have been asking for.

Accelerate the multiomic portfolio, including spatial and single-cell analysis

The push into multiomics is clear, with several key timelines. Illumina is set to introduce a single-cell Perturb-seq solution for CRISPR research by the end of 2025. This solution is planned to launch with kit formats supporting 10,000, 100,000, and 1 million cells per sample. Also, the spatial transcriptomics technology is slated for commercial release in 2026. To tie it all together, they introduced Illumina Connected Multiomics (ICM), which is their first fully integrated multimodal analysis software, helping researchers explore these complex, diverse data sets.

Introduce new AI-enhanced software for data interpretation on NovaSeq X

The NovaSeq X transition is crucial; by the end of 2025, Illumina targets approximately 75% of high-throughput gigabases shipped and around 50% of high-throughput revenue to be attributed to the NovaSeq X platform. The system itself is powerful, with the 25B flow cell delivering up to 16 Tb of output per dual flow cell run. To help interpret this massive data, Illumina announced BioInsight in October 2025, a dedicated business for scalable, AI-enabled solutions for multiomic data analysis. Plus, the DRAGEN secondary analysis v4.4, launched in May 2025, already delivers a 30% improvement in structural variant calling.

Develop new library preparation kits like Illumina Protein Prep for multiomic workflows

The Illumina Protein Prep kit, which globally launched in September 2025, is a major piece of this multiomic puzzle, offering an NGS-based proteomics assay. As of early November 2025, this solution has driven the processing of over 40,000 samples across more than 40 customers globally at 16 sites. It measures up to 9,500 unique human protein targets from a single plasma or serum sample. The workflow is fast, promising sample-to-results in under 2.5 days with only 4 hours of hands-on time. Early results with Genomics England showed a 7.5% increase in disease classification when integrating genomics and proteomics in previously undiagnosed patients.

Product/Metric	Key Performance Indicator/Scope	Status/Timeline
Illumina Protein Prep	Measures 9,500 unique human protein targets	Global launch in September 2025; over 40,000 samples processed by November 2025
Illumina Protein Prep	Time to results	Under 2.5 days total, with 4 hours hands-on time
Constellation Mapped Read Tech	Structural Variant (SV) Recall Improvement	From 51.5% (standard SBS) to 87.8% (Constellation) in early testing
Constellation Mapped Read Tech	Pilot Program Size	Evaluated 160 DNA samples with GeneDx	First commercial product slated for first half of 2026
NovaSeq X Platform	High-Throughput Revenue Attribution Target	Targeting around 50% of high-throughput revenue by end of 2025	Over 55 instrument placements reported in Q3 2025
5-Base Solution	Compatibility	NovaSeq Systems and NextSeq 2000 System	Launched October 15, 2025

Integrate Constellation mapped read technology for ultra-long phasing in 2026

The Constellation mapped read technology is designed to use on-flow-cell library prep, which eliminates the standard library prep step entirely. This approach leverages proximity information from neighboring clusters to generate long-range genomic insights using standard sequencing-by-synthesis chemistry. In a pilot project, GeneDx used this technology on its fleet of NovaSeq X Plus Systems to evaluate 160 DNA samples from individuals with known genetic disease. Early testing showed a dramatic improvement in structural variant recall, moving from 51.5% with standard SBS to 87.8% when analyzed with DRAGEN v4.3. You should expect the first commercial product based on this technology to be available in the first half of 2026, compatible with the NovaSeq X Series. That's a significant leap in resolving challenging genomic regions.

Illumina, Inc. (ILMN) - Ansoff Matrix: Diversification

You're looking at Illumina, Inc. (ILMN) moving beyond its core sequencing franchise, which, as of the second quarter of fiscal year 2025, is navigating a challenging environment with an expected total company constant currency revenue decline in the range of (2.5%) to (0.5%) for the full year. Diversification here means building new, scalable businesses that complement the existing high-throughput sequencing engine.

The new focus areas are capital-intensive, but the company ended Q2 2025 with $1.16 billion in cash, cash equivalents, and short-term investments. Management is targeting a Non-GAAP diluted EPS in the range of $4.45 - $4.55 for fiscal year 2025.

Scale the new BioInsight business unit for AI and data services

Illumina, Inc. launched BioInsight in October 2025, a dedicated business unit to meet the industry demand for interpreting large-scale multiomic data using software and Artificial Intelligence (AI). This unit is positioned at the intersection of sequencing, software, and AI. BioInsight's key focus areas include developing software solutions to analyze multimodal data at population scale and providing platforms for private, secure data access for research and pharmaceutical partners. This move is designed to accelerate drug discovery and improve disease research.

Offer large-scale, secure data platforms to pharmaceutical partners for drug discovery

The strategy involves turning data into insights by delivering a software/AI platform that integrates and analyzes large data cohorts. This is already manifesting in high-profile collaborations. For instance, a pilot proteomics program was launched in January 2025 to analyze 50,000 UK Biobank samples in partnership with deCODE Genetics and pharmaceutical giants like GSK, Johnson & Johnson, and Novartis. The resulting data quality control is expected in the second half of 2025. This directly supports the goal of expanding pharma access to large omics datasets for target discovery.

Invest in non-sequencing diagnostics, leveraging the recent GRAIL spin-off experience

The forced divestiture of GRAIL was costly, resulting in a $1.47 billion goodwill impairment charge and an additional $420 million charge for GRAIL's in-process R&D in Q2 2024. As part of the separation, Illumina, Inc. will retain a 14.5% stake in GRAIL. To comply with EU rules during the unwind, Illumina agreed to fund GRAIL for two-and-a-half years at a cost of $1 billion. Despite the financial hit, the spin-off allows Illumina, Inc. to sharpen its focus on its core sequencing business.

Acquire complementary technology in the proteomics or metabolomics space

Illumina, Inc. made a definitive move into proteomics with the announced acquisition of SomaLogic in June 2025. This acquisition is set to enhance Illumina's presence in the expanding proteomics market and advance the multiomics strategy. The deal structure involves $350 million in cash payable at closing, plus up to $75 million in near-term performance-based milestones and royalties. This brings SomaLogic's aptamer-based platform into the portfolio, aiming for high-margin consumables revenue. The resulting Illumina Protein Prep solution, launching in Q3 2025, is designed to measure 9,000 unique human proteins per sample, up from the 6,000 proteins detected during its early-access phase.

Here's a quick look at the capital deployment and financial context for these diversification efforts:

Diversification Initiative	Key Financial/Statistical Metric	Value/Amount
SomaLogic Acquisition (Proteomics)	Cash consideration at closing	$350 million
SomaLogic Acquisition (Proteomics)	Performance-based milestones/royalties	Up to $75 million
GRAIL Spin-off Impact (Diagnostics)	Goodwill Impairment Charge (Q2 2024)	$1.47 billion
GRAIL Funding Obligation (Diagnostics)	Agreed funding cost to comply with EU rules	$1 billion
BioInsight/Data Platform	Samples in UK Biobank Pilot Program	50,000
Illumina Protein Prep (Proteomics)	Unique proteins measured at launch	9,000
Q2 2025 Financial Health	Cash, cash equivalents, and short-term investments	$1.16 billion

Develop novel CRISPR-based single-cell solutions for therapeutic research

Illumina, Inc. is actively working on 'spatial transcriptomics' and 'single-cell analysis' techniques, signaling a commitment to developing novel solutions for therapeutic research. This includes an expanded research partnership with the Broad Institute of MIT and Harvard to advance single-cell sequencing and catalyze large-scale PerturbSeq CRISPR screening. This R&D investment supports the broader strategy to 'Unlock deeper biology' through complete multiomic workflows.

• Working on spatial transcriptomics techniques.
• Partnering to advance single-cell sequencing.
• Developing kits for large-scale PerturbSeq CRISPR screening.
• Focusing on multiomic workflows for deeper biological insight.